| Name | Title | Contact Details |
|---|
Turnstone Biologics, a privately held clinical stage biotech company, is developing breakthrough cancer immunotherapies by advancing two leading and complementary platforms that drive innate and adaptive tumor immunity, to provide benefit to the millions of cancer patients underserved by current treatment options. Turnstone`s proprietary vaccinia virus platform is engineered to drive coordinated immune activation, potent viral activity, and local expression of encoded therapeutics. The innovative TIL cell therapy platform leverages clinically validated treatment protocols and has been specifically designed to extend beyond the use of bulk TILs to enrich for the most relevant T-cells for tumor eradication, preserving broad antigen diversity and minimizing treatment times to patients. The Company has an ongoing Phase 1/2a trial in solid tumors (RAPTOR) for its leading oncolytic virus candidate, RIVAL-01, and is expecting to file an IND for the lead TIL therapy candidate, TIDAL-01, in 2021.
miR’s Disease Management Platform™ gives providers and patients first-time access to actionable health data, illuminating a clear path to cancer management.
Marligen Biosciences, Inc. is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Viridian Therapeutics focuses in advancing new treatments for patients with diseases that are underserved by today`s therapies.
ProteoCell Biotechnologies Inc. is a Laval, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.